Search Results

You are looking at 71 - 80 of 1,411 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Liver Transplantation for Hepatocellular Carcinoma: An Update

Jean F. Botha and Alan N. Langnas

. 3. Penn I . Hepatic transplantation for primary and metastatic cancers of the liver . Surgery 1991 ; 110 : 726 – 735 . 4. Iwatsuki S Starzl TE Sheahan DG . Hepatic resection versus transplantation for hepatocellular carcinoma

Full access

Small Cell Lung Cancer

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry M. Jahan, Marianna Koczywas, Cesar A. Moran, Harvey B. Niell, Janis O'Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, and Charles C. Williams Jr.

carcinoma differentiation. This finding is more commonly detected in specimens from previously treated patients and suggests that pulmonary carcinogenesis occurs in a pluripotent stem cell capable of differentiation along divergent pathways. Although 95

Full access

Thyroid Carcinoma

H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida

Although thyroid carcinoma is relatively uncommon, approximately 33,550 new cases will be diagnosed in the United States in 2007. It occurs 2 to 3 times more often in women than in men, and with the incidence increasing by 4% per year, it is currently the eighth most common malignancy diagnosed in women. Although it occurs more often in women, mortality rates are higher for men, probably because they are usually older at the time of diagnosis (65–69 years vs. 50–54 years in women). Interestingly, the incidence of thyroid carcinoma increased almost 240% between 1950 and 2000, but mortality rates decreased more than 44%. Important updates to the 2007 guidelines include revised criteria for categorizing disease, revised recommendation for thyroid-stimulating hormone–stimulated thyroglobulin in some cases, and expanded CT recommendations for anaplastic carcinoma.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Liver-Directed Therapies for Hepatocellular Carcinoma

Cletus A. Arciero and Elin R. Sigurdson

The authors have received a grant of less than $10,000 from the Sanofi Medical Advisory Board. References 1. Thomas MB Zhu AX . Hepatocellular carcinoma: the need for progress . J Clin Oncol 2005 ; 23 : 2892 – 2899

Full access

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Robert I Haddad, Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Lamki Busaidy, Michael Campbell, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney S. Goldner, Theresa Guo, Megan Haymart, Shelby Holt, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Dominick M. Lamonica, Susan Mandel, Stephanie Markovina, Bryan McIver, Christopher D. Raeburn, Rod Rezaee, John A. Ridge, Mara Y. Roth, Randall P. Scheri, Jatin P. Shah, Jennifer A. Sipos, Rebecca Sippel, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Michael Yeh, Carly J. Cassara, and Susan Darlow

Overview For the United States population, the lifetime risk of being diagnosed with thyroid carcinoma is 1.2%. 1 It is estimated that approximately 43,800 new cases of thyroid carcinoma will be diagnosed in the United States in 2022. 2 The

Full access

Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation

Juan Francisco Rodríguez-Moreno, María Apellaniz-Ruiz, Juan María Roldan-Romero, Ignacio Durán, Luis Beltrán, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, Jesus García-Donas, and Cristina Rodríguez-Antona

Treatment of advanced renal cell carcinoma (RCC) has changed drastically in the past decade. The mTORC1 inhibitors, everolimus and temsirolimus (also known as rapalogs ), have been shown to be key drugs for use in first-line treatment 1 and

Full access

Transplantation for Hepatocellular Carcinoma and Cholangiocarcinoma

B. Daniel Campos and Jean F. Botha

Edited by Kerrin G. Robinson

for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults . Gut 2003 ; 52 ( Suppl III ): iii1 – iii8 . 3 Llovet JM Burroughs A Bruix J . Hepatocellular carcinoma . Lancet 2003 ; 362 : 1907 – 1917 . 4 Blum

Full access

The Changing Treatment Landscape for Metastatic Urothelial Carcinoma

Thomas W. Flaig

. Flaig acknowledged this news and described the systemic treatment options for first- and second-line metastatic urothelial bladder carcinoma ( Figure 1 ). In addition, Dr. Flaig compared the similarities and differences among new immunotherapy options

Full access

Ovarian Clear Cell Carcinoma in Cowden Syndrome

Kevin Yauy, Marion Imbert-Bouteille, Virginie Bubien, Clothilde Lindet-Bourgeois, Gauthier Rathat, Helene Perrochia, Gaëtan MacGrogan, Michel Longy, Didier Bessis, Julie Tinat, Stéphanie Baert-Desurmont, Maud Blanluet, Pierre Vande Perre, Karen Baudry, Pascal Pujol, and Carole Corsini

patient first underwent laparoscopic left adnexectomy and left iliac adenopathy resection surgery. Histologic analysis revealed a 15-cm ovarian clear cell carcinoma (OCCC) with ruptured capsule associated with a 7-cm satellite nodule inside the mesosalpinx

Full access

Surgical Management of Upper Tract Transitional Cell Carcinoma

Alison M. Lake and William W. Roberts

-tract transitional-cell carcinoma . J Endourol 2005 ; 19 : 841 – 848 . 2. Chen GL Bagley DH . Ureteroscopic surgery for upper tract transitional cell carcinoma: complications and management . J Endourol 2001 ; 15 : 399 – 404 . 3. Kerbl K